CDK4/6 Inhibitors in HR+/HER2- EBC: Individualizing Therapeutic Decisions to Improve Outcomes

You must be a registrant of the European Society for Medical Oncology (ESMO) European Society for Medical Oncology in order to access this event. Registration information can be found here: https://www.esmo.org/meetings/esmo-breast-2021-virtual/registration

Agenda

Medical Need to Improve on Standard Therapies for HR+/HER2- EBC

Individualizing Therapeutic Decision-Making for Patients With HR+/HER2- EBC

Adjuvant Therapy for Patients With HR+/HER2- EBC at High Risk of Recurrence

Debating Optimal Neoadjuvant Therapy

Future Considerations on the Horizon for HR+/HER2- EBC

Summary, Final Thoughts and Q&A

Events

Date / Time
Event Details

Faculty

Faculty
Javier Cortes, MD, PhD

Head, Breast Cancer Program
Vall d’Hebron University Hospital,
Barcelona, Spain

Faculty
Stephen R D Johnston, MA, FRCP, PhD

Professor of Breast Cancer Medicine & Head of Medical Oncology,
Consultant Medical Oncologist & Head of The Breast Unit,
The Royal Marsden NHS Foundation Trust & The Institute of Cancer Research,
Fulham Road, Chelsea, London, UK.

Faculty
Sara Tolaney, MD, MPH

Assistant Professor of Medicine
Harvard Medical School
Associate Director, Susan F Smith Center for Women's Cancers
Dana-Farber/Brigham and Women's Cancer Center
Boston, MA, USA

Goal Statement
The goal of this educational curriculumis to improve the knowledge, competence, and performance of learners to plan individualized treatment for patients with HR+/HER2- EBC.

Target Audience
This educational curriculum is intended for medical oncologists, breast surgeons, and other healthcare professionals involved in the treatment of breast cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Understand the medical need for new targeted therapies to treat patients with HR+/HER2- EBC and a higher risk of recurrence along with the underlying factors affecting the decision-making process for patients and potential barriers to adoption of novel treatment options
  • Appraise current/emerging published data and consensus-based guidelines to inform the use of biomarkers and genomic classifiers to assess risk of recurrence
  • Individualize the selection of systemic therapy for appropriate patients with HR+/HER2- EBC to include CDK4/6 inhibitors with or without endocrine therapy
  • Develop strategies to anticipate, monitor, and manage adverse events with current and emerging therapies for HR+/HER2- EBC to support quality of life and continuation of treatment
  • Identify patients with HR+/HER2- EBC eligible for enrollment on ongoing clinical studies investigating novel therapies

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.